Effects of atomoxetine on cognitive function and cigarette smoking in schizophrenia.
Sacco
Kristi A
KA
Creeden
Cerissa
C
Reutenauer
Erin L
EL
Vessicchio
Jennifer C
JC
Weinberger
Andrea H
AH
George
Tony P
TP
D018759:Adrenergic Uptake Inhibitors / Q000627:therapeutic use*; D000069445:Atomoxetine Hydrochloride; D003072:Cognition Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D004298:Dopamine / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D009483:Neuropsychological Tests; D009638:Norepinephrine / Q000378:metabolism; D017397:Prefrontal Cortex / Q000187:drug effects; D011437:Propylamines / Q000627:therapeutic use*; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D012907:Smoking / Q000523:psychology*; D016540:Smoking Cessation / Q000523:psychology*
D018759:Adrenergic Uptake Inhibitors; D011437:Propylamines; D000069445:Atomoxetine Hydrochloride; D004298:Dopamine; D009638:Norepinephrine